COVID-19 Blaze-1 Study


Interested in participating in the study?

Please call (425) 650-0019 to be screened for participation and to speak with an EvergreenHealth physician about the study, and next steps. We invite your questions.


ClinicalTrials.gov Identifier: NCT04427501

The goal of the BLAZE-1 Study is to test whether the antibody medicine, LY-CoV555, helps patients with mild to moderate COVID-19 symptoms. If you have suspected COVID-19, had a COVID-19 test performed in the last 72 hours, and the test came back positive, you may be eligible to participate in BLAZE-1 Study.

Principal Investigator: Chad Crystal, MD

Key Requirements:

  • 18 years of age or older
  • Tested positive for COVID-19 with 72 hours of getting tested
  • Experiencing one or more of the following mild to moderate COVID-19 symptoms: fever, cough, sore throat, headache, muscle pain, nausea, abdominal pain, diarrhea, shortness of breath when active
  • No serious medical conditions or infections other than COVID-19
  • Not pregnant or breastfeeding
  • Not hospitalized

Participation in the BLAZE-1 Study

Participation lasts approximately 12 weeks and is made up of three sections.

1. Screening and treatment

  1. The research site staff will review your symptoms, any risk factors, and the eligibility criteria, and they will perform tests and procedures to determine if you qualify for the study.
  2. If you are eligible and decide to participate, you will be chosen (at random) to receive either the study drug or the placebo. The study drug, LY-CoV555, or placebo will be administered via IV infusion only on Day 1 of the 29-day treatment and assessment period.

2. Assessments and procedures

  1. The research team will perform certain tests and procedures to monitor your health and how your body reacts to LY-CoV555. These tests and procedures include physical exams, vital sign measurement, blood samples, and samples taken from the back of the nose to determine how much virus is in your body.

3. Follow-ups

  1. After Day 29 of the assessment period, you will enter the follow-up period. Follow-up assessments, which are less frequent visits, allow the research team to monitor how you are doing.

To learn more about the BLAZE-1 Study, click here to view the fact sheet.

Interested in participating in the study?

Please call (425) 650-0019 to be screened for participation and to speak with an EvergreenHealth physician about the study, and next steps. We invite your questions.

Thank you for your interest.